glp-1 adoption The Evolution of Users New Demand in an Old

10.1016/j.bbamem.2012.07.032 87 SchelshornD.JolyF.MutelS.HampeC.BretonB.MutelV.et al (2012)

Related incretin medicines have their own safety profiles, and the Mounjaro Side Effects article gives a broader example of how tolerability questions are usually discussed for approved therapy

These include: Nausea (the most common complaint, particularly in the first few weeks) Vomiting Diarrhoea or constipation Decreased appetite (which, while therapeutically desirable, can occasionally be excessive) Abdominal discomfort or bloating Injection-site reactions (such as redness, itching, or mild swelling at the injection site) Headache, dizziness, and fatigue , particularly during early treatment These effects are generally dose-dependent and tend to diminish as the body adjusts to the medication

35 Regional prevalence varies significantly due to ethnic, genetic, and lifestyle factors, with the lowest rates observed in Western Europe and the highest in Latin America, ranging from 25.1% to 44.3%

2022 Sep 26

All clinical trials Phase 1, Phase 2, and the Phase 3 TRIUMPH program used once-weekly dosing exclusively